Marine natural products: Bryostatins in preclinical and clinical studies

Pharmaceutical Biology

Volumn 52, Issue 2, 2014, Pages 237-242

  Kollár, Peter ^a   Rajchard, Josef ^b   Balounová, Zuzana ^b   Pazourek, Jiří ^a  

^a UNIVERSITY OF VETERINARY AND PHARMACEUTICAL SCIENCES   (Czech Republic)

^b UNIVERSITY OF SOUTH BOHEMIA   (Czech Republic)

Author keywords

Anticancer effect; Bryozoa; Carcinoma; Leukaemia; Protein kinase C

Indexed keywords

AMMONIUM TRICHLORO(DIOXYETHYLENE O,O')TELLURATE; BRYOSTATIN; BRYOSTATIN 1; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOLASTATIN 10; DOXORUBICIN; FLUDARABINE; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; PACLITAXEL; PREDNISONE; PROTEIN KINASE C; SOBLIDOTIN; TEMSIROLIMUS; VINCRISTINE;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL STUDY; CONCENTRATION RESPONSE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SAFETY; DRUG STRUCTURE; EMBRYOTOXICITY; FATIGUE; FETOTOXICITY; HUMAN; IMMUNOREACTIVITY; IMMUNOSTIMULATION; KIDNEY CARCINOMA; LARGE CELL LYMPHOMA; LONG TERM MEMORY; LUNG NON SMALL CELL CANCER; MELANOMA; MYALGIA; NAUSEA; NONHODGKIN LYMPHOMA; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PHLEBITIS; PRIMARY TUMOR; REVIEW; TERATOGENICITY; THROMBOCYTOPENIA; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; AQUATIC ORGANISMS; BIOLOGICAL PRODUCTS; BRYOSTATINS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; INVERTEBRATES; NEOPLASMS; PROTEIN KINASE C;

EID: 84891799728     PISSN: 13880209     EISSN: 17445116     Source Type: Journal    
DOI: 10.3109/13880209.2013.804100     Document Type: Review

References (35)

1. Al-Katib AM, Smith MR, Kamanda WS, et al. (1998). Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts. Clin Cancer Res 4:1305-14.
2. Baldwin NG, Rice CD, Tuttle TM, et al. (1997). Ex vivo expansion of tumor-draining lymph node cells using compounds which activate intracellular signal transduction. I. Characterization and in vivo antitumor activity of glioma-sensitized lymphocytes. J Neurooncol 32: 19-28.
3. Banerjee S, Wang Z, Mohammad M, et al. (2008). Efficacy of selected natural products as therapeutic agents against cancer. J Nat Prod 71: 492-6.
4. DeChristopher BA, Fan AC, Felsher DW, Wender PA. (2012). "Picolog, " a synthetically-available bryostatin analog, inhibits growth of MYC-induced lymphoma in vivo. Oncotarget 3:58-66.
5. Dunlap WC, Battershill CN, Liptrot CH, et al. (2007). Biomedicinals from the phytosymbionts of marine invertebrates: A molecular approach. Methods 42:358-76.
6. Haygood MG, Schmidt EW, Davidson SK, Faulkner DJ. (1999). Microbial symbionts of marine invertebrates: Opportunities for microbial biotechnology. J Mol Microbiol Biotechnol 1:33-43.
7. Hayun M, Okun E, Hayun R, et al. (2007). Synergistic effect of AS101 and bryostatin-1 on myeloid leukemia cell differentiation in vitro and in an animal model. Leukemia 21:1504-13.
8. Huang MQ, Nelson DS, Pickup S, et al. (2007). In vivo monitoring response to chemotherapy of human diffuse large B-cell lymphoma xenografts in SCID mice by 1H and 31P MRS. Acad Radiol 14: 1531-9.
9. Jayson GC, Crowther D, Prendiville J, et al. (1995). A phase-I trial of bryostatin 1 in patients with advanced malignancy using a 24-hour intravenous infusion. Br J Cancer 72:461-8.
10. Jiangbo Z, Xuying W, Yuping Z, et al. (2010). Toxicity of bryostatin-1 on the embryo-fetal development of Sprague-Dawley rats. Birth Defects Res B Dev Reprod Toxicol 89:171-4.
11. Kraft AS, Woodley S, Pettit GR, et al. (1996). Comparison of the antitumor activity of bryostatins 1, 5, and 8. Cancer Chemother Pharmacol 37:271-8.
12. Kuzirian AM, Epstein HT, Gagliardi CJ, et al. (2006). Bryostatin enhancement of memory in Hermissenda. Biol Bull 210:201-14.
13. Manning TJ, Land M, Rhodes E, et al. (2005). Identifying bryostatins and potential precursors from the bryozoan Bugula neritina. Nat Prod Res 19:467-91.
14. Mehla R, Bivalkar-Mehla S, Zhang R, et al. (2010). Bryostatin modulates latent HIV-1 infection via PKC and AMPK signaling but inhibits acute infection in a receptor independent manner. PLoS ONE 5:e11160. Available from: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0011160 [last accessed 19 Nov 2012].
15. Mohammad RM, Varterasian ML, Almatchy VP, et al. (1998a). Successful treatment of human chronic lymphocytic leukemia xeno-grafts with combination biological agents auristatin PE and bryostatin 1. Clin Cancer Res 4:1337-43.
16. Mohammad RM, Katato K, Almatchy VP, et al. (1998b). Sequential treatment of human chronic lymphocytic leukemia with bryostatin 1 followed by 2-chlorodeoxyadenosine: Preclinical studies. Clin Cancer Res 4:445-53.
17. Mohammad RM, Li Y, Mohamed AN, et al. (1999a). Clonal preservation of human pancreatic cell line derived from primary pancreatic adenocarcinoma. Pancreas 19:353-61.
18. Mohammad RM, Limvarapuss C, Hamdy N, et al. (1999b). Treatment of a de novo fludarabine resistant-CLL xenograft model with bryostatin 1 followed by fludarabine. Int J Oncol 14:945-50.
19. National Institutes of Health (NIH): Safety, efficacy, pharmacokinetics, and pharmacodynamics study of bryostatin 1 in patients with Alzheimer's disease. Available from: http://clinicaltrials.gov/ct2/show/NCT00606164 [last accessed 19 Nov 2012].
20. Newman DJ. (2012). The bryostatins. In: Cragg GM, Kingston DGI, Newman DJ, eds. Anticancer Agents from Natural Products. Boca Raton: Taylor and Francis, 199-218.
21. Oz HS, Hughes WT, Rehg JE, Thomas EK. (2000). Effect of CD40 ligand and other immunomodulators on Pneumocystis carinii infection in rat model. Microb Pathog 29:187-90.
22. Parviz M, Chin CS, Graham LJ, et al. (2003). Successful adoptive immunotherapy with vaccine-sensitized T cells, despite no effect with vaccination alone in a weakly immunogenic tumor model. Cancer Immunol Immunother 52:739-50.
23. Piel J. (2006). Bacterial symbionts: Prospects for the sustainable production of invertebrate-derived pharmaceuticals. Curr Med Chem 13:39-50.
24. Prendiville J, Crowther D, Thatcher N, et al. (1993). A phase-I study of intravenous bryostatin-1 in patients with advanced cancer. Br J Cancer 68:418-24.
25. Propper DJ, Macaulay V, O'Byrne KJ, et al. (1998). A phase II study of bryostatin 1 in metastatic malignant melanoma. Br J Cancer 78: 1337-41.
26. da Rocha AB, Lopes RM, Schwartsmann G. (2001). Natural products in anticancer therapy. Curr Opin Pharmacol 1:364-9.
27. Schaufelberger DE, Koleck MP, Beutler JA, et al. (1991). The large-scale isolation of bryostatin 1 from Bugula neritina following current good manufacturing practices. J Nat Prod 54:1265-70.
28. Schwartsmann G, da Rocha AB, Berlinck RG, Jimeno J. (2001). Marine organisms as a source of new anticancer agents. Lancet Oncol 2: 221-5.
29. Trindade-Silva AE, Lim-Fong GE, Sharp KH, Haygood MG. (2010). Bryostatins: Biological context and biotechnological prospects. Curr Opin Biotech 21:834-42.
30. Trost BM, Yang H, Dong G. (2011). Total syntheses of bryostatins: Synthesis of two ring-expanded bryostatin analogues and the development of a new-generation strategy to access the C7-C27 fragment. Chemistry 17:9789-805.
31. Ueno S, Yanagita RC, Murakami K, et al. (2012). Identification and biological activities of bryostatins from Japanese Bryozoan. Biosci Biotechnol Biochem 76:1041-3.
32. Wender PA, Hinkle KW, Koehler MF, Lippa B. (1999). The rational design of potential chemotherapeutic agents: Synthesis of bryostatin analogues. Med Res Rev 19:388-407.
33. Wender PA, Horan JC, Verma VA. (2006). Total synthesis and initial biological evaluation of new B-ring-modified bryostatin analogues. Org Lett 8:5299-302.
34. Wender PA, Verma VA. (2008). The design, synthesis, and evaluation of C7 diversified bryostatin analogues reveals a hot spot for PKC affinity. Org Lett 10:3331-4.
35. Zhang X, Zhang R, Zhao H, et al. (1996). Preclinical pharmacology of the natural product anticancer agent bryostatin 1, an activator of protein kinase C. Cancer Res 56:802-8.